Moderna Biotech Manufacturing UK Ltd carries an average payment time of 43 days, sitting 13 days beyond standard 30-day terms and indicating a consistent pattern of delayed settlement. The majority of payments (52%) fall within the 31–60 day band, suggesting that late payment is the operational norm rather than an exception. Only 40% of invoices are cleared within agreed terms, pointing to a structural payment cycle that runs longer than contracted.
With 8% of payments exceeding 60 days and a reported late payment rate of 9%, the company presents a moderate but manageable risk profile, with a small but notable tail of significantly delayed settlements. Payment behaviour is relatively predictable in that most invoices cluster in the 31–60 day window, reducing the likelihood of extreme outlier delays, though suppliers should not rely on on-time payment as a baseline. The consistency of the pattern across bands suggests this is an embedded process issue rather than isolated cash flow stress.
Suppliers considering extended credit terms with Moderna Biotech Manufacturing UK Ltd should treat 45–50 days as the realistic effective payment cycle rather than the stated 30-day terms. The risk level is moderate; the company is unlikely to default but will routinely pay late, making cash flow planning essential for smaller suppliers. It is advisable to negotiate payment terms of net 45 days contractually, apply prompt payment incentives if margin allows, and review aged debt regularly to catch the 8% of invoices at risk of exceeding 60 days.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 02 Feb 2026 | 43 | 40% | 52% | 8% | 9% |
| 01 Jan 2025 - 30 Jun 2025 | 30 Jul 2025 | 59 | 19% | 66% | 15% | 21% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Net 60 for regular companies, Net 0 for healthcare professionals, government entities, insurance companies. These payment terms apply unless specifically stated in the agreement or the SOW.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
0
In case of unpaid invoice – supplier contacts accountspayable@modernatx.com who is responsible for payment terms verification and preparing payment as soon as possible In case of quality/quantity/price difference – invoice is rejected back to supplier’s contact address by Accounts Payable based on order owner’s comment with a standard notification (wording may be slightly different depending on rejection reason): Dear Supplier, please be informed that your invoice has been rejected by order owner due to quality/quantity/price difference. Please contact your Moderna Business Contact to explain the difference. Amended invoice please resubmit to invoice@modernatx.com. Thank you for your understanding. Kind Regards, Moderna Accounts Payable Team
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
MODERNA BIOTECH MANUFACTURING UK LTD is a private limited company operating within the biotechnology and pharmaceutical manufacturing sector in the United Kingdom. The company forms part of the broader Moderna organisation, which is a globally recognised biopharmaceutical enterprise known for its work in messenger RNA (mRNA) technology and vaccine development.
The company was incorporated on 28 June 2022 and holds company registration number 14200882 with Companies House. Its registered office is located at 54 Portland Place, London, W1B 1DY, a prestigious central London address commonly used by multinational corporations establishing a UK presence.
As a biotech manufacturing entity, the company operates within a highly regulated industry governed by bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA). Companies of this nature are involved in the production, development, and supply of biological medicines, including vaccines and other advanced therapeutic products, in accordance with strict Good Manufacturing Practice (GMP) standards.
MODERNA BIOTECH MANUFACTURING UK LTD currently holds an active status with Companies House, reflecting its ongoing operational standing within the United Kingdom. Its establishment in 2022 aligns with the period following significant global expansion within the mRNA biotechnology sector.